Behind the markets
Behind the markets

Daily Trades

July 2023 Issue: Amicus Therapeutics Inc. (SYM: FOLD)

Learn More

September 2022 Issue: Mirati Therapeutics (SYM: MRTX)

Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
Learn More

UPDATE: Rhythm Pharmaceuticals (SYM: RYTM) Up 135%

A quick update and share some exciting news about one of our “Strong Buy” recommendations, Rhythm Pharmaceuticals (RYTM).
Learn More

January 2022 Issue: FDA Approvable Letter Calendar & Updates

Learn More

June 2021 Issue: Not all Obesity is the Same -Rhythm Pharmaceuticals

Learn More

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Get Deal

Categories

Behind the Markets

1.2K subscribers

Independent Research for Independent Investors

Behind the Markets
✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3Lk5NaGFZQXFhejVJ

New Housing Report Coming This Week! 👀 @MarketBeatMedia

Good morning, everyone! This is Dylan Jovine from Behind the Markets, and happy Monday! First, I want to extend my heartfelt thanks to all of you who reached out with kind words during the hurricane. Your support means a lot to me and the team here in Florida, and it motivates us to deliver our best work for you. Today, I want to talk about Jamie Dimon, the chairman and CEO of JP Morgan Chase. He’s a straight shooter and someone whose insights are worth paying attention to. Recently, JP Morgan announced earnings that exceeded expectations, but what caught my eye was Dimon’s comment that "conditions are treacherous and getting worse." This is particularly relevant given the geopolitical tensions in the Middle East and Asia, especially with China and Taiwan. Dimon also highlighted the economic landscape, expressing concerns about inflation and large fiscal deficits. He shares my cautiously optimistic outlook, shaped by decades of experience in the industry. It's crucial to stay grounded in objective facts rather than succumb to magical thinking or market euphoria. Over the years, I’ve learned that when the market is overly pessimistic, it’s often time to buy, and when it's overly optimistic, it’s a good time to sell. Thank you again for all the letters and support. It truly makes a difference, and I look forward to navigating this week together. Have a wonderful day! ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LkV3VEhMSnR2QkdF

Dylan Jovine | JP Morgan's CEO Says - "Conditions Are Treacherous and Getting Worse"

✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LmtZdERLOFNJM2hB

Commodity Price Drops: A Recession Warning? @MarketBeatMedia

Load More... Subscribe

Recent posts

Chart of Day: Barrick Gold (GOLD) – 10/14

3 Lithium Stocks Exploding – 10/14

JPMorgan CEO: “treacherous and getting worse”

Chart of Day: Trump Media & Technology Group (DJT) – 10/13

Tags

Connect with Us

Icon-facebook Icon-btmshare_tw

July 2023 Issue: Amicus Therapeutics Inc. (SYM: FOLD)

Learn More

September 2022 Issue: Mirati Therapeutics (SYM: MRTX)

Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
Learn More

UPDATE: Rhythm Pharmaceuticals (SYM: RYTM) Up 135%

A quick update and share some exciting news about one of our “Strong Buy” recommendations, Rhythm Pharmaceuticals (RYTM).
Learn More

January 2022 Issue: FDA Approvable Letter Calendar & Updates

Learn More

June 2021 Issue: Not all Obesity is the Same -Rhythm Pharmaceuticals

Learn More

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
Behind the markets

Company

Explore

CUSTOMER SERVICE

  • We’re here to help.
    Contact Us:
    Mon – Fri | 10 AM – 7 PM EST
  • 1-800-851-1965

© 2024 Behind the Markets, LLC. All rights reserved.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.